An update on myasthenic crisis

Current Treatment Options in Neurology

Volumn 7, Issue 2, 2005, Pages 129-141

  Ahmed, Shafiuddin ^b   Kirmani, Jawad F ^a   Janjua, Nazli ^b   Alkawi, Ammar ^b   Khatri, Ismail ^b   Yahia, Abutaher M ^b   Souyah, Nizar ^b   Qureshi, Adnan I ^b  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ATROPINE; AZATHIOPRINE; CHICKENPOX VACCINE; CHOLINERGIC RECEPTOR ANTIBODY; CHOLINESTERASE INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; EDROPHONIUM; GLUCOCORTICOID; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INSULIN; LOPERAMIDE; MEASLES VACCINE; MUMPS VACCINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ORAL ANTIDIABETIC AGENT; PREDNISONE; PROTEIN TYROSINE KINASE; PYRIDOSTIGMINE; QUINIDINE; RUBELLA VACCINE; STEROID; SUXAMETHONIUM; TACROLIMUS; TENSILION; UNCLASSIFIED DRUG; UNINDEXED DRUG; VECURONIUM;

ABDOMINAL CRAMP; ADRENAL CORTEX DISEASE; ALOPECIA; ARTIFICIAL VENTILATION; ASEPTIC NECROSIS; ASPIRATION; BRAIN PSEUDOTUMOR; CARBOHYDRATE TOLERANCE; CARDIOMYOPATHY; CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONGESTIVE HEART FAILURE; CONVULSION; CUSHINGOID SYNDROME; DIABETES MELLITUS; DIARRHEA; DISEASE EXACERBATION; DRUG COST; DRUG EFFICACY; ELECTRODIAGNOSIS; ENDOTRACHEAL INTUBATION; FEVER; FLUID RETENTION; FRACTURE; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; HEADACHE; HEART ARRHYTHMIA; HEMORRHAGIC CYSTITIS; HIRSUTISM; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERVOLEMIA; HYPOKALEMIC ALKALOSIS; HYPOPHYSIS DISEASE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFECTION; INTENSIVE CARE UNIT; INTERMETHOD COMPARISON; INTRACRANIAL HYPERTENSION; KIDNEY DISEASE; KIDNEY DYSFUNCTION; LEUKOPENIA; LIFESPAN; LIVER DYSFUNCTION; LUNG FUNCTION TEST; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DECISION MAKING; MENSTRUATION DISORDER; MUSCLE DISEASE; MUSCLE WEAKNESS; MYALGIA; MYASTHENIA GRAVIS; MYOPATHY; NASOGASTRIC TUBE; NAUSEA; NAUSEA AND VOMITING; NEUROMUSCULAR JUNCTION DISORDER; NEUROPATHY; OSTEOPOROSIS; PAPILLEDEMA; PEPTIC ULCER; PLASMAPHERESIS; PNEUMONIA; POLYNEUROPATHY; POTASSIUM DEPLETION; PROGNOSIS; RANDOMIZATION; RESPIRATORY FAILURE; REVIEW; RISK REDUCTION; SALIVATION DISORDER; SEIZURE; SEPSIS; SIDE EFFECT; SODIUM RETENTION; STOMACH HEMORRHAGE; STOMACH PERFORATION; TENDON RUPTURE; THYMECTOMY; TREATMENT PLANNING; TREMOR; VERTEBRA FRACTURE; VERTIGO; VOMITING; WOUND HEALING IMPAIRMENT;

EID: 14744299451     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-005-0022-2     Document Type: Review

References (41)

1. Fink ME: Treatment of critically ill patient with myasthenia gravis. In Neurology and Neurosurgical Intensive Care, Edition 3. Edited by Ropper AH. New York: Raven Press; 1993:351-362.
2. Wilks S: On cerebritis, hysteria, and bulbar paralysis, as illustrative of arrest of function of the cerebrospinal centers. Guy's Hospital Report 1877, 22:7-55.
3. Pascuzzi RM: The history of myasthenia gravis. Neurol Clin 1994, 12:231-242.
4. Drachman DB: Myasthenia gravis. N Engl J Med 1994, 330:1797.
5. Phillips II LH: The epidemiology of myasthenia gravis. Neurol Clin 1994, 12:263-271.
6. Qureshi AI, Choudhry MA, Mohammad Y, et al.: Respiratory failure as a first presentation of myasthenia gravis. Med Sci Monitor 2004, 10:CR684-689.
7. Kubis KC, Danesh-Meyer HV, Savino PJ, Sergott RC: The Ice test versus the rest test in myasthenia gravis. Ophthalmology 2000, 107:1995-1998.
8. Lertchavanakul A, Gamnerdsiri P, Hirunwiwatkul P: Ice test for ocular myasthenia gravis. J med Assoc Thai 2001, 84(suppl 1):S131-136.
9. Hoch W, McConville J, Helms S, et al.: Auto-antibodies to the receptor tyrosine kinase musk in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001, 7:365-368.
10. Wilkins KB, Bulkley GB: Thymectomy in the integrated management of myasthenia gravis. Adv Surg 1999, 32: 05-133.
11. Bedlack RS, Sanders DB: How to handle myasthenic crisis. Essential steps in patient care. Postgrad Med 2000, 107: 11-214.
12. Mayer SA: Intensive care of the myasthenic patient. Neurology 1997, 48:70-75S.
13. Berrouschot J, Baumann I, Kalischewski P, et al.: Therapy of myasthenic crisis. Crit Care Med 1997, 25: 228-1235.
14. Thomas CE, Mayer SA, Gungor Y, et al.: Myasthenic crisis: Clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology 1997, 48:1253-1260.
15. Qureshi AI, Bhardwaj A, Ulatowski JA: Neurocritical care for the house officer. In ICU Care House Officer Series. Edited by Helfaer M. Baltimore: Williams & Wilkins; 1998:65,92.
16. Janjua N, Mayer SA: Myasthenic crisis. In Critical Care Neurology and Neurosurgery, Edition 1. Edited by Suarez JI. New Jersey: Humana Press; 2004:469-480.
17. Younger DS, Raksadawan N: Therapy in neuromuscular disease. Neurol Clin 2001, 19:205-215.
18. Mayer SA, Thomas CE: Therapy of myasthenic crisis. Crit Care Med 1998, 26:1136-1137.
19. London SF RS: Neuromuscular emergencies. In Emergent and Urgent Neurology. Edited by Weiner WJ. Philadelphia: JB Lippincott; 1992:59-78.
20. Rieder P, Louis M, Jolliet P, Chevrolet JC: The repeated measurement of vital capacity is a poor predictor of the need for mechanical ventilation in myasthenia gravis. Intensive Care Med 1995, 21:663-668.
21. Tripathi M, Kaushik S, Dubey P: The effect of use of pyridostigmine and requirement of vecuronium in patients with myasthenia gravis. J Postgrad Med 2003, 49:311-314; Discussion 314-315.
22. Qureshi AI, Choudhry MA, Akbar MS, et al.: Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology 1999, 52:629-632.
23. Gajdos P, Chevret S, Clair B, et al.: Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia gravis clinical study group. Ann Neurol 1997, 41:789-796.
24. Stricker RB, Kwiatkowska BJ, Habis JA, Kiprov DD: Myasthenic crisis: Response to plasmapheresis following failure of intravenous gamma-globulin. Arch Neurol 1993, 50:837-840.
25. Qureshi AI, Suri MF: Plasma exchange for treatment of myasthenia gravis: Pathophysiologic basis and clinical experience. Ther Apher 2000, 4:280-286.
26. Wolfe GI, Barohn RJ, Foster BM, et al.: Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis. Muscle Nerve 2002, 26:549-552.
27. Confavreux C, Saddier P, Grimaud J, et al.: Risk of cancer from azathioprine therapy in multiple sclerosis: A case-control study. Neurology 1996, 46:1607-1612.
28. Meriggioli MN, Rowin J, Richman JG, Leurgans S: Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study. Ann N Y Acad Sci 2003, 998: 94-499.
29. Meriggioli MN, Rowin J: Single fiber EMG as an outcome measure in myasthenia gravis: results from a double-blind, placebo-controlled trial. J Clin Neurophysiol 2003, 20: 82-385.
30. De Feo LG, Schottlender J, Martelli NA, Molfino NA: Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis. Muscle Nerve 2002, 26:31-36.
31. Takamori M, Motomura M, Kawaguchi N, et al.: Anti-ryanodine receptor antibodies and FK506 in myasthenia gravis. Neurology 2004, 62:1894-1896.
32. Utsugisawa K, Nagane Y, Yonezawa H, et al.: Effects of fk506 on myasthenia gravis patients with high interleukin-2 productivity in peripheral blood mononuclear cells. Muscle Nerve 2003, 27:245-248.
33. Evoli A, Di Schino C, Marsili F, Punzi C: Successful treatment of myasthenia gravis with tacrolimus. Muscle Nerve 2002, 25:111-114.
34. Gordon MY, Goldman JM, Gordon-Smith EC: 4-hydroperoxycyclophosphamide inhibits proliferation by human granulocyte-macrophage colony-forming cells (GM-CFC) but spares more primitive progenitor cells. Leuk Res 1985, 9:1017-1021.
35. Jones RJ, Barber JP, Vala MS, et al.: Assessment of aldehyde dehydrogenase in viable cells. Blood 1995, 85: 742-2746.
36. Drachman DB, Jones RJ, Brodsky RA: Treatment of refractory myasthenia: "rebooting" with high-dose cyclophosphamide. Ann Neurol 2003, 53:29-34.
37. Romi F, Gilhus NE, Varhaug JE, et al.: Thymectomy and antimuscle antibodies in nonthymomatous myasthenia gravis. Ann N Y Acad Sci 2003, 998:481-490.
38. Wolfe GI, Kaminski HJ, Jaretzki III A, et al.: Development of a thymectomy trial in nonthymomatous myasthenia gravis patients receiving immunosuppressive therapy. Ann N Y Acad Sci 2003, 998:473-480.
39. Kissel JT, Franklin GM: Treatment of myasthenia gravis: A call to arms. Neurology 2000, 55:3-4.
40. Soleimani A, Moayyeri A, Akhondzadeh S, et al.: Frequency of myasthenic crisis in relation to thymectomy in generalized myasthenia gravis: A 17-year experience. BMC Neurol 2004, 4: 2.
41. Cohen MS, Younger D: Aspects of the natural history of myasthenia gravis: Crisis and death. Ann N Y Acad Sci 1981, 377:670-677.